ConductScience.org, home

Paper41398705

Malignant hypertension and pseudohyperaldosteronism associated with rifampicin therapy.

Szedleski A and 4 others. Cardiovasc Diabetol Endocrinol Rep, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Malignant hypertension and pseudohyperaldosteronism associated with rifampicin therapy. Papers, record 41398705. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41398705

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Malignant hypertension and pseudohyperaldosteronism associated with rifampicin therapy.
PubMed
Journal
Cardiovasc Diabetol Endocrinol Rep
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-12-18
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Szedleski AAlexandre
2Ilbert CCédric
3Goncette VVéronique
4Vroonen LLaurent
5Huart JJustine

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References24

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11345893Case report: nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension.Am J Med Sci1992https://conductscience.org/library/papers/1345893PubMed
231581123Adrenal insufficiency, be aware of drug interactions!Endocrinol Diabetes Metab Case Rep2019https://conductscience.org/library/papers/31581123PubMed
312882588Pharmacokinetic interactions with rifampicin : clinical relevance.Clin Pharmacokinet2003https://conductscience.org/library/papers/12882588PubMed
412892318Pseudohyperaldosteronism: pathogenetic mechanisms.Crit Rev Clin Lab Sci2003https://conductscience.org/library/papers/12892318PubMed
532100890Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System.Pharmacotherapy2020https://conductscience.org/library/papers/32100890PubMed
627251484Syndromes that Mimic an Excess of Mineralocorticoids.High Blood Press Cardiovasc Prev2016https://conductscience.org/library/papers/27251484PubMed
738794208Concomitant Treatment with Doxycycline and Rifampicin in Balb/c Mice Infected with Brucella abortus 2308 Fails to Reduce Inflammation and Motor Disability.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/38794208PubMed
821295138Nuclear receptor PXR, transcriptional circuits and metabolic relevance.Biochim Biophys Acta2011https://conductscience.org/library/papers/21295138PubMed
930756059Addison's Disease Caused by Tuberculosis: Diagnostic and Therapeutic Difficulties.Eur J Case Rep Intern Med2018https://conductscience.org/library/papers/30756059PubMed
1060596Letter: Induction of hepatic cortisol-6-hydroxylase by rifampicin.Lancet1976https://conductscience.org/library/papers/60596PubMed
1135229613Pregnane X Receptor‒4β-Hydroxycholesterol Axis in the Regulation of Overweight- and Obesity-Induced Hypertension.J Am Heart Assoc2022https://conductscience.org/library/papers/35229613PubMed
1226956190Apparent mineralocorticoid excess.J Steroid Biochem Mol Biol2017https://conductscience.org/library/papers/26956190PubMed
1330872343Tuberculous Addison's disease with increased hydrocortisone requirements due to administration of rifampicin.BMJ Case Rep2019https://conductscience.org/library/papers/30872343PubMed
1416973756Activation of pregnane X receptor disrupts glucocorticoid and mineralocorticoid homeostasis.Mol Endocrinol2007https://conductscience.org/library/papers/16973756PubMed
1532344455Pregnane X Receptor Activator Rifampin Increases Blood Pressure and Stimulates Plasma Renin Activity.Clin Pharmacol Ther2020https://conductscience.org/library/papers/32344455PubMed
1632918434Resistant hypertension during antituberculosis treatment: how is rifampicin implicated?Med J Malaysia2020https://conductscience.org/library/papers/32918434PubMed
1728407303Rifampicin reverses nicardipine effect inducing uncontrolled essential hypertension.Fundam Clin Pharmacol2017https://conductscience.org/library/papers/28407303PubMed
1827795624Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact.Indian J Nephrol2016https://conductscience.org/library/papers/27795624PubMed
1932434261[Drug-drug Interactions in Intensive Care].Anasthesiol Intensivmed Notfallmed Schmerzther2020https://conductscience.org/library/papers/32434261PubMed
20212193984β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.Br J Clin Pharmacol2011https://conductscience.org/library/papers/21219398PubMed

See all 24 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CYP4F34051PubTator's text mininghttps://conductscience.org/library/genes/4051NCBI Gene
NR1I28856PubTator's text mininghttps://conductscience.org/library/genes/8856NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41398705

GET https://conductscience.org/api/papers/v1/41398705/references?page=2